Clinical trial
Omega-3 Fatty Acid Treatment in Multiple Sclerosis
NCT00360906 · Haukeland University Hospital, Other · Completed
Key facts
| NCT number | NCT00360906 |
|---|---|
| Title | Omega-3 Fatty Acid Treatment in Multiple Sclerosis |
| Official title | Omega-3 Fatty Acid Treatment in Multiple Sclerosis |
| Lead sponsor | Haukeland University Hospital, Other |
| Collaborators | The Multiple Sclerosis National Competence Centre The Norwegian Multiple sclerosis Society Pronova BioPharma Industry Serono Nordic Amersham Health |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Triomar™ (omega-3 fatty acids) |
| Enrollment | 100 |
| Start date | Dec 1, 2004 |
| Completion | Jul 1, 2008 |
| First posted | Aug 7, 2006 |
| Last update posted | Aug 7, 2006 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: